Category: BioTech

BioTech

Biotech Active Stocks: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Rexahn Pharmaceuticals (NYSEMKT:RNN), Peregrine Pharmaceuticals (NASDAQ:PPHM)

Inovio Pharmaceuticals Inc (NYSEMKT:INO) raises $63 million, secures capital needs for near-term trial advancement and preparation to enter Phase lll studies. Inovio Pharmaceuticals Inc (NYSEMKT:INO) dropped -1.96 percent to $3.51 yesterday on volume of INO 6.88million shares. The intra-day range of the stock was $3.50 to $3.71. Inovio Pharmaceuticals Inc (NYSEMKT:INO) has a market capitalization of $795.32million. After announcing two years ago that it would … Continue reading Biotech Active Stocks: MannKind Corporation (NASDAQ:MNKD), Inovio Pharmaceuticals (NYSEMKT:INO), Rexahn Pharmaceuticals (NYSEMKT:RNN), Peregrine Pharmaceuticals (NASDAQ:PPHM)

Richard Atkins
BioTech

Healthcare Active runners: Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Galena Biopharma (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD)

Officials with Zogenix Inc. (NASDAQ:ZGNX), the San Diego-based maker of Zohydro, did not return a message seeking comment about the drug. The company is marketing the drug as the first extended-release hydrocodone pain reliever without acetaminophen, which can cause liver failure if taken in excess. Zogenix, Inc. (NASDAQ:ZGNX) stock performance was -14.18% in last session and finished the day at $3.84. Traded volume was 9.38million … Continue reading Healthcare Active runners: Zogenix (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX), Galena Biopharma (NASDAQ:GALE), Gilead Sciences (NASDAQ:GILD)

Kristen Barton
BioTech

SolarWinds (NYSE:SWI) Price Target Increased by Jefferies

On Wednesday, Jefferies raised it’s price target for SolarWinds (NYSE:SWI) to $57 from $51.  In a research note issued by Aaron Schwartz, he indicated that the company’s cash flow potential remains underappreciated.  The stock continues to be a stock favorite at Jefferies. Highlights of the note included: 20% license growth could serve as a baseline. Stable ASPs with recent levels, and productivity from 2013 sales … Continue reading SolarWinds (NYSE:SWI) Price Target Increased by Jefferies

Mark DeFrance
BioTech

Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Peregrine Pharmaceuticals (NASDAQ:PPHM) is scheduled to be releasing its Q314 earnings data on Friday, March 7th. Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was 47.64% in last session and finished the day at $2.82. Traded volume was 36.76million shares in the last session and the average volume of the stock remained 3.12million shares. The beta of the stock remained 1.40. Peregrine Pharmaceuticals (NASDAQ:PPHM) insider ownership is 16%. … Continue reading Healthcare Active Runners: Peregrine Pharmaceuticals (NASDAQ:PPHM), Bristol-Myers Squibb (NYSE:BMY), Abbott Laboratories (NYSE:ABT), Teva Pharmaceutical Industries (NYSE:TEVA)

Colin Pettis
BioTech

Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Insys Therapeutics (NASDAQ:INSY), NPS Pharmaceuticals (NASDAQ:NPSP), XOMA Corp (NASDAQ:XOMA)

The Rosen Law Firm, P.A. reminds purchasers of Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR) between March 15, 2012 and January 9, 2014, inclusive (the “Class Period”) of the important Mach 17, 2014 lead plaintiff deadline in the class action seeking remedies under the federal securities laws. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) stock performance was -5.40% in last session and finished the day at $53.74. Traded volume was 1,222,609 … Continue reading Biotech Losers: Aegerion Pharmaceuticals (NASDAQ:AEGR), Insys Therapeutics (NASDAQ:INSY), NPS Pharmaceuticals (NASDAQ:NPSP), XOMA Corp (NASDAQ:XOMA)

Richard Atkins
BioTech

Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)

Equities research analysts at Deutsche Bank assumed coverage on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $45.00 price target on the stock. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was 24.46% in last session and finished the day at $26.31. Traded volume was 7,684,553 million shares in the … Continue reading Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)

Mark DeFrance